Replimune (REPL) soars 86% as WSJ says White House intervention reopens RP1 review

Replimune Group, Inc. (NASDAQ: REPL), the Woburn, Massachusetts clinical-stage biotechnology company developing cancer-killing viral immunotherapies, saw its shares surge nearly 86 percent after a report that White House officials intervened to convince the Food and Drug Administration to reconsider its twice-rejected lead drug. According to The Wall Street Journal, citing people familiar with the matter, the intervention cleared the way for Replimune to submit a marketing application for RP1 in advanced melanoma for a third time despite two prior rejections. The stock closed at 8.69 dollars, up from a prior close of 4.68 dollars, on volume of more than 50 million shares, as traders rushed to price in a sharply higher probability of eventual approval. The episode is extraordinary not for new clinical data, of which there was none, but for the rare spectacle of political intervention reshaping an individual drug review. For investors, it transforms a stock left for dead after regulatory defeat into a high-stakes wager on whether RP1 finally reaches the market.

What did the Wall Street Journal report about the White House intervention on Replimune’s RP1?

The core of the report is a regulatory reversal driven from outside the agency. The Wall Street Journal reported that White House officials pressed the Food and Drug Administration to accept a third submission of Replimune’s biologics license application for RP1, the company’s lead asset, after the agency had rejected it twice. Replimune separately confirmed it plans to resubmit following what it described as a productive discussion with the regulator.

The agency’s posture appears to have shifted markedly. Replimune said the Food and Drug Administration indicated it would treat the resubmission as an urgent matter and prioritize its review, language that signals a far more accommodating stance than the rejections that preceded it. For a drug that had been blocked twice, a commitment to expedited review is a substantial change in fortune.

The catalyst is unusual precisely because it is not scientific. Biotech stocks typically move on trial readouts, advisory committee votes, or approval decisions, but here the driver is reported political pressure on the regulator. That distinction matters for how investors should weigh the move, because a path reopened by intervention rather than by new evidence carries a different and arguably less predictable risk profile than a standard regulatory win.

Why did the FDA reject Replimune’s RP1 melanoma drug twice before this reversal?

The rejections centered on trial design rather than safety. In July 2025, the Food and Drug Administration issued a complete response letter declining to approve RP1, raising concerns that the pivotal IGNYTE study enrolled a heterogeneous patient population and was not an adequate and well-controlled trial capable of supporting approval on its own. The agency also questioned aspects of tumor assessment methodology.

Replimune contested the agency’s reasoning at each turn. The company resubmitted with additional analyses, including data showing no material difference in response between injected and non-injected lesions and evidence that biopsies and surgical interventions did not affect tumor response, arguing these addressed the regulator’s concerns. When the Food and Drug Administration issued a second rejection in April 2026, Replimune publicly disagreed, maintaining that the data underpinning the drug’s breakthrough therapy designation were sufficient to justify making it available to advanced cancer patients.

The dispute escalated into the public arena ahead of the reversal. A prominent newspaper editorial defended RP1 earlier in the year, and reports circulated that the agency official associated with the rejection might be removed, both of which lifted the shares before the latest news. The saga illustrates a genuine scientific disagreement, between a regulator demanding randomized, controlled evidence and a company arguing that durable responses in a deadly disease warrant a more flexible standard.

How strong is the clinical case for RP1 in advanced melanoma after anti-PD-1 failure?

The clinical signal is meaningful, which is what makes the case contentious. In the IGNYTE trial, RP1 combined with the immunotherapy nivolumab produced an objective response rate of 34 percent in patients whose advanced melanoma had progressed on a prior anti-PD-1 regimen, with a median duration of response of 24.8 months. Responses lasting more than two years in heavily pretreated patients are clinically important in a setting with limited options.

The depth of benefit in responders strengthens the argument. Among patients who responded, outcomes extended to roughly 30.6 months compared with about 4.4 months on their prior anti-PD-1 based regimen, a dramatic difference that underpinned the drug’s breakthrough therapy designation. RP1 is an oncolytic immunotherapy built on an engineered herpes simplex virus designed to kill tumor cells directly and provoke a systemic immune response, and it is paired with nivolumab, the checkpoint inhibitor marketed by Bristol Myers Squibb.

The weakness, and the crux of the regulatory fight, is the trial’s structure. The data come largely from a single-arm setting rather than a randomized controlled comparison, which the Food and Drug Administration has argued makes it difficult to isolate RP1’s contribution from that of nivolumab or from patient selection. Strong response and durability numbers are persuasive to clinicians treating desperate patients, but they do not automatically satisfy the statistical bar regulators traditionally require, which is why reasonable experts have disagreed about whether the drug should be approved.

Why did Replimune stock nearly double and what does the 52-week range reveal?

The price action reflects a binary bet being repriced. Replimune shares jumped roughly 86 percent to close at 8.69 dollars, within a 52-week range that runs from 1.50 dollars to 13.24 dollars, leaving the stock back toward the middle of that band after having collapsed following the rejections. The enormous trading volume underscores that the move was driven by a wholesale reassessment of approval odds rather than incremental positioning.

The range itself tells the story of a roller-coaster year. The stock fell to its lows after the regulatory defeats wiped out much of the value that had been built on approval expectations, and it has whipsawed on each twist in the saga, including the editorial defense and reports about agency personnel. A clinical-stage company with no approved products and a market capitalization around 700 million dollars on roughly 82 million shares is inherently volatile, and RP1’s fate is close to an all-or-nothing determinant of the equity’s worth.

The valuation now embeds renewed optimism that is not yet justified by an approval. Analyst views remain cautious and widely dispersed, with consensus closer to hold and price targets spanning a broad range, reflecting deep uncertainty about whether a third submission succeeds. Investors buying after an 86 percent jump are paying for a probability of approval that has improved but remains far from certain, which leaves the stock exposed to a sharp reversal if the review does not go Replimune’s way.

What does political intervention in an FDA decision mean for biotech and regulatory norms?

The episode sits at the intersection of patient advocacy and regulatory independence, and reasonable observers see it very differently. Supporters of the intervention argue that the Food and Drug Administration was overly rigid in demanding randomized data for a drug showing durable responses in a lethal disease with few alternatives, and that expediting access reflects appropriate urgency for terminally ill patients who cannot wait for a perfect trial.

Critics view the same facts as a worrying precedent. They contend that political pressure on an individual drug decision risks undermining the agency’s scientific independence and the consistency of its standards, potentially opening the door for future approvals to be influenced by lobbying, public campaigns, or political priorities rather than evidence. The concern is less about RP1 specifically than about the principle of insulating regulatory judgment from outside intervention.

For the broader biotech sector, the implications cut in two directions. A more flexible regulatory environment could accelerate approvals and benefit companies developing therapies for unmet needs, supporting valuations across the space. At the same time, unpredictability in how decisions are made raises the risk premium investors must apply, because a process that can be reopened by intervention can presumably also be influenced against a company. The net effect on sector sentiment will depend on whether this proves an isolated case or the start of a pattern.

What clinical, regulatory and financial risks remain for Replimune investors now?

The first risk is that acceptance is not approval. The Food and Drug Administration agreeing to review a third submission removes one barrier, but the agency could still decline to approve RP1 after evaluating the package, particularly given the unresolved questions about trial design that drove the earlier rejections. The stock has priced in improved odds, so a negative decision would likely trigger a steep fall.

The second risk is financial. Replimune is a clinical-stage company with no product revenue and a substantial cash burn, having reported a net loss of roughly 70.9 million dollars in a single recent quarter. Funding continued operations and a commercial launch, if approval comes, may require additional capital, and equity raises at depressed prices would dilute shareholders, a perennial hazard for pre-revenue biotechs.

The third risk is commercial and competitive, assuming approval is eventually secured. RP1 would enter a melanoma market with established therapies, and as an injectable oncolytic immunotherapy used in combination with nivolumab, its uptake would depend on physician adoption, reimbursement, and real-world results. Replimune’s broader pipeline, including the RP2 candidate being studied in uveal melanoma, liver cancer, and other tumors under a collaboration with Roche, offers additional shots on goal, but the company’s near-term value is overwhelmingly tied to RP1. For investors, the stock has shifted from pricing failure to pricing a contested second chance, and the wide range of outcomes makes it a speculative position rather than a settled recovery.

Key takeaways on what the RP1 reversal means for Replimune and biotech investors

• Replimune shares surged nearly 86 percent to 8.69 dollars after The Wall Street Journal reported White House officials pushed the FDA to accept a third submission of its twice-rejected drug RP1.
• The catalyst was political rather than clinical, with no new trial data, which makes the rally a repricing of approval odds rather than a response to fresh evidence.
• The FDA rejected RP1 in July 2025 and again in April 2026, citing concerns that the IGNYTE trial was not an adequate and well-controlled study.
• RP1 with nivolumab showed a 34 percent response rate and a 24.8 month median duration of response in advanced melanoma after anti-PD-1 failure, earning breakthrough therapy designation.
• The core scientific dispute is single-arm data versus the randomized, controlled evidence regulators traditionally require.
• The intervention divides observers, with supporters citing urgent unmet need and critics warning about the erosion of FDA scientific independence.
• For the sector, a more flexible regulator could speed approvals but unpredictability raises the risk premium investors must apply.
• Acceptance of the submission is not approval, and a negative decision would likely reverse much of the stock’s gain.
• As a pre-revenue biotech with a roughly 70.9 million dollar quarterly loss, Replimune faces dilution risk from potential capital raises.
• The stock is now a speculative bet on a contested second chance, with RP1’s outcome the dominant driver of value alongside the RP2 pipeline.